Table 1 Clinical characteristics of 16 patients with CMML stratified by ASXL1 genotype.
Parameter | Unit | ASXL1WT (n = 8) | ASXL1MT (n = 8) |
|---|---|---|---|
Age at diagnosis | [years] | 66 (12) | 67 (13) |
Male sex | [n (%)] | 4 (50) | 6 (75) |
Hemoglobin | [g/dL] | 12.3 (3.3) | 11.6 (4.4) |
Leukocytes | [x109/L] | 8.4 (9) | 14.2 (23.9) |
Neutrophils | [x109/L] | 3.2 (3.8) | 6.5 (15.2) |
Lymphocytes | [x109/L] | 2.3 (2.1) | 1.9 (1.4) |
Monocytes | [x109/L] | 2.0 (4.5) | 2.8 (2.5) |
Platelets | [x109/L] | 112 (60) | 159 (151) |
Peripheral blood blasts | [%] | 0 (2) | 0 (1) |
Bone marrow blasts | [%] | 4 (3) | 2 (5) |
Abnormal cytogenetics | [n (%)] | 3 (38) | 3 (38) |
Morphology (WHO 2016) | |||
CMML-0 | [n (%)] | 5 (62) | 4 (50) |
CMML-1 | [n (%)] | 1 (13) | 3 (37) |
CMML-2 | [n (%)] | 2 (25) | 1 (13) |
Mayo Prognostic Model | |||
Low | [n (%)] | 3 (37) | 0 (0) |
Intermediate | [n (%)] | 2 (25) | 4 (50) |
High | [n (%)] | 3 (38) | 4 (50) |
Mayo Molecular Model | |||
Low | [n (%)] | 3 (37) | 0 (0) |
Intermediate-1 | [n (%)] | 2 (25) | 0 (0) |
Intermediate-2 | [n (%)] | 3 (38) | 4 (50) |
High | [n (%)] | 0 (0) | 4 (50) |
Leukemic transformation | [n (%)] | 4 (50) | 5 (63) |
